Assertio Therapeutics (ASRT) Tops Q3 EPS by 16c; Raises FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Assertio Therapeutics Announces Third-Quarter 2018 Financial Results
November 8, 2018 4:06 PM EST-- Confirms Full-Year Net Sales Guidance Range for the Neurology Franchise ---- Raises Full-Year Earnings Guidance and Confirms Adjusted EBITDA Guidance ---- Amends and Strengthens Commercial Agreement with Collegium ---- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End --
LAKE FOREST, Ill., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today reported financial results for the quarter ended September 30, 2018, and provided an update on its business performance and strategic initiatives.
Our third-quarter performance positions us well to... More
